CTRI/2022/09/045600尚未招募未知
A Randomised Controlled Trial of Fasting and Surgery Timing (FaST) in a tertiary care referral centre ââ?¬â?? Is it time for the ââ?¬Ë?Think Drinkââ?¬â?¢ campaign? - FaST
Mario Victor Newton0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients admitted for elective surgery.
- •(Operations were defined using the NCEPOD classification of surgical intervention. Elective operations were defined as intervention planned or booked in advance of routine admission to hospital. Timing tosuit patient, hospital and staff.)
排除标准
- •Emergency cases, cases planned under local anesthesia, Diabetics, Chronic Liver Disease
研究者
相似试验
尚未招募
1 期
A Single-Dose study under fasting condition to assess the Bioequivalence of Etoricoxib 120 mg tablets (Test formulation), provided by DKSH (Thailand) Limited with a reference formulation Arcoxia® 120 mg tablets, in 24 healthy volunteersBioequivalence studyBioequivalenceEtoricoxibTCTR20181008002Bio-innova and Synchron.Co.,Ltd24
尚未招募
1 期
A Single-Dose study under fasting condition to assess the Bioequivalence of Febuxostat 80 mg tablets (Test formulation), provided by DKSH (Thailand) Limited with a reference formulation Feburic(R) 80 mg tablets, in 32 healthy volunteersBioequivalence studyFebuxostatTCTR20200916003Bio-innova and Synchron.Co.,Ltd32
已完成
不适用
Monocentric longitudinal Study to Fasting Effects on Energy and Bone MetabolismE66.9R63.2Obesity, unspecifiedPolyphagiaDRKS00004249KLinik Buchinger Bodensee GmbH55
尚未招募
Unknown
Study to observe the safety of fasting and improvement in aging indices in healthy adultsJPRN-UMIN000052921Juntendo University80
尚未招募
1 期
A single dose study under fasting condition to access the Bioequivalence of Etoricoxib 120 mg tablets (Test formulation), manufactured by Interthai Pharmaceutical Manufacturing Limited with a reference formulation Arcoxia® - MSD, in 24 healthy volunteersBioequivalence study in healthy volunteersBioequivalence,EtoricoxibTCTR20170201002Bio-innova and Synchron.Co.,Ltd24
